Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Among authors: thistlethwaite f. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. Naing A, et al. Among authors: thistlethwaite f. J Immunother Cancer. 2021 Jul;9(7):e002447. doi: 10.1136/jitc-2021-002447. J Immunother Cancer. 2021. PMID: 34301809 Free PMC article.
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Någård M, Ah-See ML, So K, Vermunt M, Thistlethwaite F, Labots M, Roxburgh P, Ravaud A, Campone M, Valkenburg-van Iersel L, Ottesen L, Li Y, Mugundu G. Någård M, et al. Among authors: thistlethwaite f. Cancer Chemother Pharmacol. 2020 Jul;86(1):97-108. doi: 10.1007/s00280-020-04101-4. Epub 2020 Jun 16. Cancer Chemother Pharmacol. 2020. PMID: 32556602 Free PMC article. Clinical Trial.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Sanborn RE, Hamid O, de Vries EG, Ott PA, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Cho DC, Plummer R, Stroh M, Lu L, Thistlethwaite F. Sanborn RE, et al. Among authors: thistlethwaite f. J Immunother Cancer. 2021 Jul;9(7):e002446. doi: 10.1136/jitc-2021-002446. J Immunother Cancer. 2021. PMID: 34301808 Free PMC article. Clinical Trial.
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M, Jiang Y, Lorigan PC, Thistlethwaite FC, Thomas M, Kirillova N, Bridgeman JS, Kueberuwa G, Biswas S, Velazquez P, Chonzi D, Guest RD, Roberts ZJ, Hawkins RE. Pillai M, et al. Am J Cancer Res. 2022 Aug 15;12(8):3967-3984. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119832 Free PMC article.
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.
Owen K, Ghaly R, Shohdy KS, Thistlethwaite F. Owen K, et al. Among authors: thistlethwaite f. Cancer Immunol Immunother. 2023 Apr;72(4):805-814. doi: 10.1007/s00262-022-03287-1. Epub 2022 Oct 31. Cancer Immunol Immunother. 2023. PMID: 36315268 Free PMC article. Review.
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.
Shohdy KS, Pillai M, Abbas KS, Allison J, Waddell T, Darlington E, Mohammad S, Hood S, Atkinson S, Simpson K, Morgan D, Nathan P, Kilgour E, Dive C, Thistlethwaite F. Shohdy KS, et al. Among authors: thistlethwaite f. Immunooncol Technol. 2024 Mar 18;22:100712. doi: 10.1016/j.iotech.2024.100712. eCollection 2024 Jun. Immunooncol Technol. 2024. PMID: 38694705 Free PMC article.
Engineering T cells for cancer therapy.
Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Mansoor W, et al. Among authors: thistlethwaite fc. Br J Cancer. 2005 Nov 14;93(10):1085-91. doi: 10.1038/sj.bjc.6602839. Br J Cancer. 2005. PMID: 16251873 Free PMC article. Review.
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, Shablak A, Shanks J, Liptrot T, Thistlethwaite F, Hawkins RE. Chow S, et al. Among authors: thistlethwaite f. J Immunother Cancer. 2016 Oct 18;4:67. doi: 10.1186/s40425-016-0174-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 27777776 Free PMC article.
53 results